Clinical trial
A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
NCT03733925 is registered in ClinicalTrials.gov with Johnson & Johnson Private Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
- Lead sponsor
- Johnson & Johnson Private Limited
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 7, 2019
- Completion date
- November 15, 2021
- Enrollment
- 100 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.